Moderna

Nasdaq Announces Moderna to Join Nasdaq-100 Index, Replacing Warner Bros. Discovery

Nasdaq announced that Moderna, Inc. will replace Warner Bros. Discovery, Inc. in the Nasdaq-100 Index, effective October 9, 2026, before market open. This change reflects Moderna's increasing market value and the index's focus on innovative companies, potentially boosting investor interest and trading volume for Moderna. The Nasdaq-100 Index tracks 100 of the largest non-financial companies listed on Nasdaq and is a significant benchmark globally.

Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026

Nasdaq announced that Moderna, Inc. (MRNA) will be added to the Nasdaq-100 Index®, replacing Warner Bros. Discovery, Inc. (WBD), effective prior to market open on October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is a widely recognized benchmark for investment products. This change highlights Moderna's growing market presence and significance in the non-financial sector.

Weekly Market Update: Stocks Gain 1.09% as Technology Rises, Energy Falls

The Morningstar US Total Market Index rose 1.09% for the trading week ending Sept. 25, driven by strong performance in technology and healthcare sectors, while energy and utilities declined. Moderna, Datadog, Cadence Design Systems, Perrigo Company, and Qualcomm were among the top stock gainers. Conversely, Gen Digital, Cogent Communications Holdings, MGM Resorts International, Jersey Mike’s Subs, and Paychex were the week's biggest losers.

Moderna Stock Reached New 52-Week High: What's Happening?

Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has been accepted for the European Society for Medical Oncology Congress. Despite the rally and promising trial results, Bernstein SocGen Group maintained a "Market Perform" rating and a $45 price target, expressing skepticism about the stock's current valuation.

Bernstein reiterates Moderna stock rating on mRNA platform progress

Bernstein SocGen Group has reiterated a Market Perform rating and a $45.00 price target for Moderna Inc. (NASDAQ: MRNA) shares, despite the stock's significant surge over the past year. Analysts highlighted that Intismeran validates the broader mRNA therapeutics platform, with promising melanoma data expected. However, InvestingPro analysis suggests the stock is currently overvalued, leading to mixed sentiment among other analysts.

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen (OCGN) received provisional approval and priority designation in the Bahamas for its experimental gene therapy, OCU400, aimed at treating retinitis pigmentosa. This marks a significant step in the company's global expansion efforts, with plans to treat the first patient in the Bahamas within 90 days. Ocugen also has other late-stage eye-disease programs and is pursuing commercialization opportunities in various international markets.

BioNTech SE (22UA.F) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.

Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals

Moderna, Inc. (MRNA) stock surged nearly 7% to a 52-week high of $194.82, displaying a strong bullish trend above all major moving averages. However, technical indicators like the daily RSI14 at 75.12 and price trading above the upper Bollinger Band suggest the stock is overbought and may be due for a pause or consolidation. While the overall trend remains bullish, short-term momentum on hourly charts shows signs of cooling, warranting disciplined positioning.

Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Analysts

Moderna, Inc. (NASDAQ:MRNA) has received a consensus "Hold" recommendation from analysts, with four suggesting a sell, thirteen a hold, and seven a buy. The average 12-month price target is significantly lower than its current share price, yet the company reported better-than-expected quarterly revenue and a slightly narrower loss per share. While its mRNA pipeline shows promise, insider selling and a high valuation pose potential risks.

Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.

Moderna's stock surged 7% following investor optimism surrounding its personalized cancer vaccine, intismeran autogene, ahead of Phase 3 melanoma data presentation at ESMO on October 24. Despite the jump, the stock's current price of $195 significantly surpasses the average analyst target of $120. CEO Stéphane Bancel also reframed Moderna as an mRNA platform company, focusing on oncology and rare diseases, rather than solely a COVID-19 vaccine developer.

Moderna Stock Trends After Hours - Moderna (NASDAQ:MRNA), Merck & Co (NYSE:MRK)

Moderna (MRNA) shares are trending after hours following an announcement regarding its investigational mRNA-based individualized neoantigen therapy, intismeran autogene. The company will present three abstracts, including Phase 3 trial data evaluating intismeran with Merck & Co.'s (MRK) pembrolizumab, at the European Society for Medical Oncology Congress 2026. MRNA stock saw a significant jump of 6.98% during regular trading and edged higher in after-hours trading.

MAIA Biotechnology expands pivotal Phase 3 THIO-104 NSCLC trial into Spain and Portugal

MAIA Biotechnology has secured regulatory approval from Spain's AEMPS and Portugal's INFARMED to enroll patients for its pivotal Phase 3 THIO-104 trial in non-small cell lung cancer (NSCLC). This expansion into new markets, which together account for approximately 30,000 new lung cancer cases annually, aims to broaden patient access to the investigational therapy and help the Chicago-based company meet its enrollment targets for a key interim survival analysis in 2027. THIO-104 is a first-in-class telomere-targeting agent, and the trial has already enrolled 65 patients with advanced NSCLC.

Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN

This article highlights several biotech stocks that reached 52-week highs on September 23, 2026, due to positive developments. Alpha Teknova Inc. (TKNO) saw growth from new products and increased revenue, while Moderna Inc. (MRNA) achieved highs after positive Phase 3 trial results for its melanoma treatment. AtriCure Inc. (ATRC) recorded strong revenue growth with its FDA-approved Afib treatments, and Illumina Inc. (ILMN) climbed due to significant revenue growth in genomics.

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

TriSalus Life Sciences Inc. received FDA 510(k) clearance for its TriNav Advance, an expansion of its Pressure-Enabled Drug Delivery (PEDD) platform for interventional oncology. Despite the clearance, the stock, trading as TLSI, saw a slight decline on Wednesday but maintains a constructive long-term technical outlook above key moving averages. The article highlights critical resistance at $6.00 and support at $4.50, noting the importance of breaking above the resistance for continued upward momentum.

Biotech Stock Decoy Therapeutics (NASDAQ: DCOY) Leads Nasdaq Top Gainers on News of FDA Animal Rule Pathway

Decoy Therapeutics (NASDAQ: DCOY) shares became a top Nasdaq gainer after the company announced it is advancing a pan-filovirus D-MAV program through the FDA's Animal Rule pathway. This strategy aims for expedited regulatory approval and allows Decoy to pursue non-dilutive government grants and biodefense partnerships. The program targets Ebola, Marburg, Sudan, and Bundibugyo viruses, with potential eligibility for a Priority Review Voucher worth $100 million to $180 million.

Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis

Moderna Inc. (MRNA) saw its stock rise by 5.16% due to positive market reaction to strong Phase 3 oncology trial data for its personalized cancer therapy and regulatory clearances for updated COVID-19 vaccines. Despite this recent upward momentum and positive analyst upgrades, the company faces ongoing challenges such as operational cash burn, net losses, and potential equity dilution from recent convertible note issuances. Investors are keenly awaiting detailed Phase 3 data, which will be a critical catalyst to justify the stock's current valuation amidst existing risks and some analyst downgrades.

Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Moderna's stock (MRNA) has surged over 500% in 2026, significantly outperforming its rival BioNTech, primarily due to positive top-line results from its personalized cancer therapy, intismeran, in a melanoma trial. The market is now keenly awaiting detailed Phase 3 data on October 24 at the ESMO Presidential Symposium, which carries significant binary risk for the stock's future trajectory. Investors are advised to consider the potential for either validation of the rally or a sharp compression of the stock's valuation based on the upcoming data.

Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."

Moderna's stock has seen a significant surge due to positive clinical trial data for its mRNA-based cancer vaccine, co-developed with Merck. Despite this, many Wall Street analysts maintain a neutral or "hold" rating, with some downgrading the stock, believing the market has overreacted and that future trial results or immediate economic impacts are uncertain. Investors are advised to be cautious, with some experts suggesting waiting for the hype to subside before making long-term commitments, especially given recent share dilution through convertible debt.

UBS reiterates Moderna stock rating ahead of melanoma data

UBS has reiterated a Neutral rating on Moderna Inc. (NASDAQ: MRNA) with a $150.00 price target ahead of anticipated Phase III melanoma trial results. The stock has seen significant movement, trading at $180.30, up over 20% in the past week, and near its 52-week high. The market is keenly awaiting the melanoma study results, expecting a hazard ratio of 0.65 or better, which could lead to a 10-20% stock increase, though InvestingPro analysis suggests the stock is currently overvalued.

Lunai Bioworks partners with Tanaist to enhance Parkinson's disease research using human cellular validation.

Lunai Bioworks has announced an exclusive worldwide license and collaboration with Tanaist to integrate human cellular phenotyping into its AI-driven Parkinson's disease platform. This partnership aims to validate patient subtypes identified by Lunai's AI tools by connecting them to biological mechanisms and biomarkers. The collaboration will strengthen Lunai's efforts to translate AI discoveries into effective treatments for Parkinson's disease.

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna's shares surged 9% after its Phase 3 melanoma vaccine study for intismeran autogene was selected for a Presidential Symposium slot at the ESMO congress, signaling significant clinical potential. While no new efficacy data was released, the prestigious slot itself indicates the data is considered practice-changing. Merck, Moderna's partner, and BioNTech saw modest gains, suggesting the market views this as a re-rating specific to Moderna rather than a broad validation of mRNA oncology.

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.

Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines

Forge Nano and Nanexa have entered a Joint Development Agreement to advance manufacturing for ALD-coated PharmaShell® long-acting injectable medicines. This collaboration aims to develop large-scale, GMP-compliant ALD manufacturing equipment to support Nanexa’s PharmaShell® drug delivery platform and its portfolio of proprietary and partnered programs. The agreement will combine Nanexa’s drug delivery expertise with Forge Nano’s industrial ALD process development to create flexible and scalable manufacturing capabilities for a broad range of pharmaceutical products.

CNH Industrial Prices C$550 Million of Privately Placed Notes

CNH Industrial N.V. has priced C$550 million of privately placed notes. The company is an equipment and services provider specializing in agricultural and construction equipment. This announcement follows recent news of emissions-system software updates and strategic alliances for seeding lines.

Establishment Labs presents clinical data, expands product lines

Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced the presentation of clinical and scientific data for its Breast Tissue Preservation technology and Minimally Invasive Platform at the 11th World Symposium on Ergonomic Implants. The company also introduced product line extensions for its Mia and Preservé products, including new sizes and supporting tools. This expansion aligns with the growth in the breast augmentation market and solidifies the foundation for future advancements in the field.

Moderna, Inc. (MRNA) To Present Phase 3 Melanoma Data at ESMO; Investor Webcast Set

Moderna (MRNA) is scheduled to present late-breaking Phase 3 data for its intismeran autogene in resected stage IIB–IV melanoma at the ESMO 2026 conference. The company will also host an investor webcast on October 24th to discuss these results. The acceptance of three abstracts, including a Presidential Symposium slot, highlights the perceived importance of this data, which could significantly impact Moderna's oncology pipeline and valuation.

Guggenheim raises BlossomHill Therapeutics price target to $40 on pipeline progress By Investing.com

Guggenheim has increased its price target for BlossomHill Therapeutics (NASDAQ: BLSM) to $40 from $30, maintaining a Buy rating, following promising pipeline advancements for its lead asset BH-30643 in lung cancer treatment. The company also reported strong Q2 2026 results and has a robust cash position, with $95 million in cash and equivalents and $168 million from its August 2026 IPO, extending its cash runway beyond major clinical readouts. JPMorgan also initiated coverage with an Overweight rating and a $28 price target, indicating growing confidence in the company's potential.

Westlake Chemical Partners offers a steady 9% yield backed by a fixed-margin contract through 2027.

Westlake Chemical Partners (WLKP) provides a reliable 9% yield, supported by a fixed-margin, cost-plus contract valid until 2027, and has consistently maintained distributions for 48 quarters, shielding cash flows from market volatility. Although its growth prospects are limited and distribution increases are improbable, WLKP is considered an attractive option for income-focused investors due to its stable yield and current valuation, which is about 10% below the sector median. The main risk factor involves the contract renewal process post-2027.

Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week

Moderna (MRNA) shares surged to a three-year high in anticipation of upcoming pipeline updates, particularly at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum. The company is expected to present further Phase 3 trial data for its melanoma treatment candidate, intismeran autogene combined with Merck’s Keytruda, which previously showed positive results in recurrence-free and distant metastasis-free survival. This news highlights the potential of its mRNA-based cancer therapy in a large addressable market, increasing investor confidence despite a slight decrease in the number of hedge funds holding the stock.

Moderna stock hits 52-week high at 176.75 USD

Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology sector, particularly its COVID-19 vaccine development. However, InvestingPro analysis advises caution due to high price volatility and expectations of unprofitability this year, suggesting the stock may be overvalued.

Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’

Moderna will present detailed Phase 3 results for its personalized cancer therapy, Intismeran, at the ESMO Congress on October 24, 2026. This therapy, developed with Merck, previously showed significant improvements in melanoma recurrence-free and distant metastasis-free survival when combined with Keytruda. Retail investors are increasingly optimistic about Moderna's stock, with some believing this cancer therapy could be revolutionary.

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

Moderna (NASDAQ: MRNA) announced that three abstracts for its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026. These presentations will detail phase 3 study results for resected melanoma, phase I study results for resectable pancreatic ductal adenocarcinoma, and a phase 3 study of adjuvant intismeran autogene for high-risk stage I NSCLC. Moderna will also host a live webcast investor event during the congress to discuss these findings.

Amgen stock last at USD 410.86, up 1.19 percent in New York trading

Amgen's stock closed at USD 410.86 in New York trading, marking a 1.19 percent increase. This rise surpassed the S&P 500's gain, despite elevated long-term Treasury yields and ongoing market uncertainties. The company's stock demonstrated resilience with an intraday range from USD 404.19 to USD 411.00.

Prime Medicine Gets FDA Green Light for Gene Editing Study

Prime Medicine (NASDAQ: PRME) has received FDA clearance for its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company plans to initiate a global Phase 1/2 clinical trial to assess the safety and efficacy of PM647, which aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene. PM647 is designed to restore functional M-AAT protein levels to address both liver and lung complications of AATD.

Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?

Pfizer distributed $48.8 billion in dividends and buybacks over the last five years, yet its stock experienced a total return of -16.8% during the same period, significantly underperforming the S&P 500. This paradox highlights the challenge for mature, profitable companies to generate shareholder value when growth lags, emphasizing the importance of a strong R&D pipeline to sustain long-term growth and justify capital return policies. Investors are left questioning whether generous payouts compensate for a declining stock value without future growth drivers.

Schwab, Fidelity, E-Trade Top Investing Rankings In IBD Trust Survey

A recent Investor's Business Daily (IBD) survey found that Schwab, Fidelity, and E-Trade are the top-ranked investment firms for trust. The article highlights that while performance in managing assets like stocks and ETFs is important, client trust is considered the most valuable asset for wealth management firms. This survey emphasizes the critical role of trust when clients entrust their savings to these financial institutions.

Mizuho raises Charles River Labs stock price target to $295 on outlook

Mizuho increased its price target for Charles River Laboratories International Inc. (NYSE:CRL) to $295 from $264, while maintaining a Neutral rating, following the company's Investor Day. The upward adjustment reflects Mizuho's increased confidence in the durable recovery of biopharma demand and the company's potential for sustainable growth, as the new financial targets exceeded expectations. Despite the positive outlook and strong past performance, Mizuho kept a Neutral rating due to valuation concerns, as InvestingPro analysis suggests the stock is currently overvalued.

Coca-Cola’s Secret Dividend Weapon Is a Business Model Most Investors Overlook

Coca-Cola's consistent dividend growth for over 60 years is attributed to its asset-light business model, primarily selling concentrate and syrup to bottlers, which results in high gross margins and strong free cash flow. This model allows KO to comfortably cover its substantial dividend payments, unlike peers PepsiCo and Keurig Dr Pepper who have heavier reinvestment burdens. While the free cash flow coverage is robust, investors should monitor the company's relatively high earnings-based payout ratio and projected EPS growth for future dividend sustainability.

Merck shares may rise as key clinical trial results in oncology and other areas approach.

Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating due to upcoming clinical trial data in oncology and other pipeline areas. Key trials include Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with presentations expected at the European Society for Medical Oncology meeting. Despite a recent dip, Merck maintains a strong market cap and positive investor interest.

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

The global autologous hematopoietic stem cell gene therapy market is projected to grow significantly, reaching $13.44 billion by 2030 from $5.23 billion in 2025, driven by advancements in gene-editing, increased investment in rare disease treatments, and personalized therapies. Key growth factors include commercialization of gene-editing therapies, regulatory approvals, adoption of personalized medicine, and infrastructure investments. North America was the largest regional market in 2025, with Asia-Pacific expected to be the fastest-growing region.

Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast

Helus Pharma (operating as Cybin Inc.) CEO Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company is advancing HLP003, a Phase 3 novel serotonergic agonist (NSA) with FDA Breakthrough Therapy Designation for major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder. This participation highlights the company's late-stage pipeline for mental health conditions.

Kailera Therapeutics (Nasdaq:KLRA) - Stock Analysis

Kailera Therapeutics (KLRA) is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related conditions. The company recently reported positive Phase 3 data for its oral GLP-1 receptor agonist KAI-7535, showing significant weight loss and HbA1c reductions. KLRA is preparing for global Phase 3 trials for its Ribupatide candidates and has appointed a new CTO, indicating late-stage development and commercialization efforts, despite current unprofitability and a short cash runway.

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.

Is Halliburton (NYSE:HAL) Stock Worth Watching Today?

Halliburton (NYSE:HAL) is worth watching due to service demand influenced by crude oil volatility and its impact on drilling budgets. The broader market is characterized by selective trading, emphasizing business quality, operating consistency, and sector-specific demand amidst fluctuating interest rates, energy prices, and global trade discussions. The article highlights the importance of company-specific execution and demand signals to assess Halliburton's performance within the nuanced oil and gas sector.

Is SLB (NYSE:SLB) Stock Worth Watching Today?

SLB (NYSE:SLB) is currently in focus due to oilfield activity amidst easing crude prices and moderating supply concerns. The article emphasizes that the broader market remains selective, prioritizing business quality and consistent operations, making company-specific execution crucial for oil and gas stocks. Future clarity on SLB's performance will depend on upcoming company communications regarding demand, operations, and sector conditions.

Is AbbVie (NYSE:ABBV) Stock Worth Watching Today?

AbbVie (NYSE:ABBV) is a relevant stock to watch today as defensive healthcare demand supports the sector. The market is selective, focusing on business quality and execution amid varied macroeconomic factors like interest rates, energy prices, and technology interest. The company's business model durability and customer demand signals will be key in understanding its performance within the current market environment.

First Trust High Yield Opportunities 2027 Fund faces volatility but offers a unique exit via a likely tender offer.

The First Trust High Yield Opportunities 2027 Term Fund (FTHY) is currently experiencing volatility and a widening discount despite its approaching liquidation date. It is anticipated that the fund's term structure may lead to a vote to convert it to a perpetual fund, which would likely include a tender offer for existing shares. Current holders are advised to participate in this tender offer, as discounts typically widen further after such events.

We Think Meta Could Keep Soaring Higher and Wells Fargo Agrees

Wells Fargo has significantly increased its price target for Meta Platforms from $640 to $796, reiterating an Overweight rating, based on strong AI product momentum and early success of the Meta Muse assistant. The firm points to a 60% jump in daily assistant users since Muse Spark integration and expects Meta Connect to highlight these usage statistics. This upgrade reinforces a rebuilding bull case for Meta, particularly for long-term investors, despite some near-term risks like compressed operating margins and a surge in capital expenditures.